| Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study (NCT07435779) | Hebei Senlang Biotechnology Inc., Ltd. | 2026-02-04 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases (NCT07161193) | Hebei Senlang Biotechnology Inc., Ltd. | 2025-09-30 |
| Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL (NCT07244406) | Hebei Senlang Biotechnology Inc., Ltd. | 2025-01-10 |
| the Safety and Efficacy of SENL103 Autologous T Cell Injection (NCT06067581) | Hebei Senlang Biotechnology Inc., Ltd. | 2023-08-21 |
| CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study (NCT06136364) | Hebei Senlang Biotechnology Inc., Ltd. | 2023-08-15 |
| The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies (NCT05618041) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-09-07 |
| Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL (NCT05626400) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-08-29 |
| SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies (NCT05398614) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-05-01 |
| Universal CAR-γδT Cell Injection in the AML Patients (NCT05388305) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-04-20 |
| To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors (NCT05388695) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-04-08 |
| The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. (NCT05333588) | Hebei Senlang Biotechnology Inc., Ltd. | 2022-02-15 |
| Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia (NCT05225831) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-08-15 |
| Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia (NCT04938115) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-05-10 |
| Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT05206071) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-05-01 |
| Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma (NCT04928105) | Hebei Senlang Biotechnology Inc., Ltd. | 2021-01-27 |
| Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation (NCT04796441) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-12-16 |
| Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04792593) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-12-03 |
| Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors (NCT04665076) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-10-22 |
| A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma (NCT04666168) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-10-22 |
| Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells (NCT04572308) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-10-01 |
| Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia (NCT04546893) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-09-01 |
| Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04546906) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-09-01 |
| Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors (NCT04556669) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-08-01 |
| Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04447547) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-06-30 |
| Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04447573) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-06-30 |
| Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children (NCT04610125) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-06-23 |
| CAR-T Cells in the Treatment of Malignant Hematological Tumors (NCT05619861) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-27 |
| CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia (NCT04626765) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-01 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory NHL (NCT04626739) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-01 |
| Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation (NCT04626726) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-01 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04626752) | Hebei Senlang Biotechnology Inc., Ltd. | 2020-04-01 |
| Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia (NCT03840317) | Hebei Senlang Biotechnology Inc., Ltd. | 2019-01-02 |
| Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia (NCT03796390) | Hebei Senlang Biotechnology Inc., Ltd. | 2018-12-26 |